The Q1 2023 quarterly report can be accessed using the link below
Learn MoreDedicated to the treatment of metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach
Browse our resources hub for the latest news and information
Learn More
About us
Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach.
Product pipeline
Our expertise in small molecules has enabled a strong pipeline with potential first/best-in-class drug candidates.
Investors
Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.